Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
BCRX BioCryst Pharmaceuticals	$9.57 -1.0%	$9.92	$6.02 ▼ $11.31	$2.00B	1.11	3.01 million shs	1.68 million shs
CLDX Celldex Therapeutics	$20.99 -0.9%	$20.12	$14.40 ▼ $47.00	$1.39B	1.33	939,109 shs	325,730 shs
FOLD Amicus Therapeutics	$5.83 +2.4%	$6.30	$5.51 ▼ $12.65	$1.79B	0.54	3.09 million shs	1.84 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BCRX BioCryst Pharmaceuticals	-0.82%	-3.01%	-10.47%	+22.90%	+56.31%
CLDX Celldex Therapeutics	-1.35%	+1.68%	+7.03%	+6.22%	-41.37%
FOLD Amicus Therapeutics	+0.53%	-0.70%	-8.81%	-32.50%	-41.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	4.4132 of 5 stars	4.4	2.0	0.0	4.2	2.0	1.7	0.6
CLDX Celldex Therapeutics	2.5834 of 5 stars	4.4	3.0	0.0	0.0	2.1	0.0	0.0
FOLD Amicus Therapeutics	4.1388 of 5 stars	3.4	2.0	0.0	4.3	2.5	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVEO AVEO Pharmaceuticals	0.00	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	73.05% Upside
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	138.75% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	178.49% Upside

Current Analyst Ratings Breakdown

Latest AVEO, BCRX, FOLD, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
BCRX BioCryst Pharmaceuticals	$503.49M	3.98	N/A	N/A	($2.30) per share	-4.16
CLDX Celldex Therapeutics	$7.02M	198.47	N/A	N/A	$11.26 per share	1.86
FOLD Amicus Therapeutics	$528.29M	3.40	N/A	N/A	$0.65 per share	8.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.20	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.55	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)

Latest AVEO, BCRX, FOLD, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
CLDX Celldex Therapeutics	N/A	21.67	21.67
FOLD Amicus Therapeutics	2.02	3.34	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVEO AVEO Pharmaceuticals	49.95%
BCRX BioCryst Pharmaceuticals	85.88%
CLDX Celldex Therapeutics	N/A
FOLD Amicus Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVEO AVEO Pharmaceuticals	3.29%
BCRX BioCryst Pharmaceuticals	4.80%
CLDX Celldex Therapeutics	4.40%
FOLD Amicus Therapeutics	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable

AVEO, BCRX, FOLD, and CLDX Headlines

Recent News About These Companies

Amicus Therapeutics stock hits 52-week low at $5.55

June 25 at 9:51 AM | investing.com

Japan approves Amicus Therapeutics' treatment for late-onset Pompe disease

June 25 at 7:30 AM | investing.com

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

June 25 at 7:00 AM | globenewswire.com

Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment

June 24 at 6:33 PM | msn.com

Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month Low - Time to Sell?

June 23, 2025 | marketbeat.com

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

June 20, 2025 | globenewswire.com

SG Americas Securities LLC Acquires 58,496 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 20, 2025 | marketbeat.com

Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week Low - Time to Sell?

June 17, 2025 | marketbeat.com

Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.22

June 17, 2025 | americanbankingnews.com

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

June 16, 2025 | globenewswire.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts

June 14, 2025 | marketbeat.com

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

June 13, 2025 | globenewswire.com

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

June 12, 2025 | globenewswire.com

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

June 12, 2025 | seekingalpha.com

Wedge Capital Management L L P NC Decreases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 11, 2025 | marketbeat.com

Zacks Research Analysts Decrease Earnings Estimates for FOLD

June 6, 2025 | marketbeat.com

New Strong Sell Stocks for June 3rd

June 3, 2025 | zacks.com

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

June 3, 2025 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 471,902 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 1, 2025 | marketbeat.com

Two Sigma Advisers LP Buys 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 1, 2025 | marketbeat.com

Two Sigma Investments LP Boosts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVEO, BCRX, FOLD, and CLDX Company Descriptions

AVEO Pharmaceuticals NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.57 -0.09 (-0.96%)

As of 11:47 AM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics NASDAQ:CLDX

$20.99 -0.18 (-0.85%)

As of 11:47 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics NASDAQ:FOLD

$5.82 +0.14 (+2.37%)

As of 11:47 AM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time